Blinatumomab Bridging Therapy in High-Risk B-Acute Lymphoblastic Leukemia: A Phase 2 Study
Latest Information Update: 21 May 2025
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 13 May 2025 Status changed from recruiting to discontinued.
- 27 Jan 2021 Status changed from not yet recruiting to recruiting.
- 21 Sep 2020 New trial record